Longitudinal Clinical Outcomes After Intra‐Articular Dexamethasone–Lidocaine Injection for Temporomandibular Joint Arthralgia

BACKGROUND: Longitudinal real-world data on intra-articular dexamethasone-lidocaine injection for temporomandibular joint (TMJ) arthralgia remain limited. This study evaluated post-injection clinical trajectories in patients with TMJ arthralgia. METHODS: This retrospective observational study included 191 patients (45.5 ± 20.7 years; 67.5% female) with TMJ arthralgia who received intra-articular dexamethasone-lidocaine injection. Mean follow-up from baseline injection to the last available follow-up was 77.0 ± 82.7 days. Outcomes included visual analogue scale (VAS), comfortable mouth opening (CMO), maximum mouth opening (MMO), pain presence, and pain-location burden. Paired, longitudinal, and final-outcome analyses were performed, with additional exploratory analyses. RESULTS: At first follow-up, VAS decreased from 3.25 ± 1.75 to 2.45 ± 1.67 (change, -0.80 ± 1.44; FDR-adjusted p < 0.001), CMO increased modestly by 0.99 ± 5.98 mm (FDR-adjusted p = 0.015), and pain-location burden decreased by 0.30 ± 0.90 (FDR-adjusted p < 0.001). MMO did not change significantly (FDR-adjusted p = 0.166). Mixed-effects models using actual elapsed time showed decreases in VAS (β = -0.069 per 30 days; FDR-adjusted p = 0.003) and pain-location burden (β = -0.093 per 30 days; FDR-adjusted p < 0.001) and a modest increase in CMO (β = 0.343 mm per 30 days; FDR-adjusted p = 0.001), whereas MMO showed no significant longitudinal change. The absolute VAS decrease was greater in the moderate-to-severe baseline pain group than in the mild pain group (-1.68 ± 1.56 vs. -0.35 ± 1.13; FDR-adjusted p < 0.001). At final follow-up, VAS had decreased from baseline in 53.4% of patients, including 80.0% of those with moderate-to-severe baseline pain (FDR-adjusted p < 0.001). CONCLUSIONS: Intra-articular dexamethasone-lidocaine injection was followed by decreases in pain intensity and pain-location burden and a modest increase in CMO, whereas MMO showed no consistent longitudinal change. These findings support a multidomain approach to assessing clinical trajectories after TMJ injection.

Authors

Institutions

Publication Details

Journal
Journal of Oral Rehabilitation
Published
2026-11-20
DOI
https://doi.org/10.1111/joor.70347
Primary Topic
Temporomandibular Joint Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal Clinical Outcomes After Intra‐Articular Dexamethasone–Lidocaine Injection for Temporomandibular Joint Arthralgia

Yung‐Kyun Noh, Tae-Seok Kim, Yeon‐Hee Lee
Journal of Oral Rehabilitation
Temporomandibular Joint Disorders
article

Longitudinal Clinical Outcomes After Intra‐Articular Dexamethasone–Lidocaine Injection for Temporomandibular Joint Arthralgia

Yung‐Kyun Noh, Tae-Seok Kim, Yeon‐Hee Lee
article en

Abstract

BACKGROUND: Longitudinal real-world data on intra-articular dexamethasone-lidocaine injection for temporomandibular joint (TMJ) arthralgia remain limited. This study evaluated post-injection clinical trajectories in patients with TMJ arthralgia. METHODS: This retrospective observational study included 191 patients (45.5 ± 20.7 years; 67.5% female) with TMJ arthralgia who received intra-articular dexamethasone-lidocaine injection. Mean follow-up from baseline injection to the last available follow-up was 77.0 ± 82.7 days. Outcomes included visual analogue scale (VAS), comfortable mouth opening (CMO), maximum mouth opening (MMO), pain presence, and pain-location burden. Paired, longitudinal, and final-outcome analyses were performed, with additional exploratory analyses. RESULTS: At first follow-up, VAS decreased from 3.25 ± 1.75 to 2.45 ± 1.67 (change, -0.80 ± 1.44; FDR-adjusted p < 0.001), CMO increased modestly by 0.99 ± 5.98 mm (FDR-adjusted p = 0.015), and pain-location burden decreased by 0.30 ± 0.90 (FDR-adjusted p < 0.001). MMO did not change significantly (FDR-adjusted p = 0.166). Mixed-effects models using actual elapsed time showed decreases in VAS (β = -0.069 per 30 days; FDR-adjusted p = 0.003) and pain-location burden (β = -0.093 per 30 days; FDR-adjusted p < 0.001) and a modest increase in CMO (β = 0.343 mm per 30 days; FDR-adjusted p = 0.001), whereas MMO showed no significant longitudinal change. The absolute VAS decrease was greater in the moderate-to-severe baseline pain group than in the mild pain group (-1.68 ± 1.56 vs. -0.35 ± 1.13; FDR-adjusted p < 0.001). At final follow-up, VAS had decreased from baseline in 53.4% of patients, including 80.0% of those with moderate-to-severe baseline pain (FDR-adjusted p < 0.001). CONCLUSIONS: Intra-articular dexamethasone-lidocaine injection was followed by decreases in pain intensity and pain-location burden and a modest increase in CMO, whereas MMO showed no consistent longitudinal change. These findings support a multidomain approach to assessing clinical trajectories after TMJ injection.

Journal of Oral Rehabilitation
Korea Institute for Advanced Study (KR), Seoul National University (KR), Kyung Hee University (KR), Kyung Hee University Dental Hospital (KR), Seoul National University Dental Hospital (KR), Hanyang University (KR)
Temporomandibular Joint Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon